Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken.
Watch this short video to learn why!

FDA’s Proposed Reclassification of Oncology Immunohistochemistry (IHC) Test Systems

$129.99

Stay ahead in oncology diagnostics with a thorough course on the FDA’s proposed rule to reclassify immunohistochemistry (IHC) test systems used alongside approved oncology therapeutics. Gain detailed insights into the new regulatory landscape, covering the rationale for moving from class III (premarket approval) to class II (special controls), affected device codes, identified risks, and new expectations for performance data and labeling. This course prepares you for regulatory compliance, clinical implementation, and effective stakeholder participation in shaping future requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification.
* Describe the regulatory framework for medical device classification.
* Identify the scope and types of IHC test systems affected.
* Recognize the risks and benefits associated with these devices.
* Explain the proposed special controls and their role in ensuring safety and effectiveness.
* Navigate the public comment process and understand the importance of stakeholder engagement.
* Appreciate that the rule is not final and may change based on public input.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.

Why This Course is Important
Without this course, you could miss essential knowledge on upcoming regulatory changes, risk mitigation strategies, and the opportunity to influence the FDA’s final rule—potentially resulting in compliance gaps or missed market opportunities.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product.

Key regulatory references include:

Course SKU
FR-26-3326-1

About Benchmarks:

Are you ready for this regulation? Use this benchmark to find out.

Each benchmark is build directly for the federal regulation.  They reflect the learning objectives of the related course.

The benchmark is not a “trivia test” – they help you evaluate your readiness to apply the new regulation.

Contact us for more information and/or personalized benchmarks for your specific organization/industry.

FDA’s Proposed Reclassification of Oncology Immunohistochemistry (IHC) Test Systems

Stay ahead in oncology diagnostics with a thorough course on the FDA’s proposed rule to reclassify immunohistochemistry (IHC) test systems used alongside approved oncology therapeutics. Gain detailed insights into the new regulatory landscape, covering the rationale for moving from class III (premarket approval) to class II (special controls), affected device codes, identified risks, and new expectations for performance data and labeling. This course prepares you for regulatory compliance, clinical implementation, and effective stakeholder participation in shaping future requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification.
* Describe the regulatory framework for medical device classification.
* Identify the scope and types of IHC test systems affected.
* Recognize the risks and benefits associated with these devices.
* Explain the proposed special controls and their role in ensuring safety and effectiveness.
* Navigate the public comment process and understand the importance of stakeholder engagement.
* Appreciate that the rule is not final and may change based on public input.

NOTE: Unless otherwise indicated, all Benchmarks are free of charge!

Why This Course is Important
Without this course, you could miss essential knowledge on upcoming regulatory changes, risk mitigation strategies, and the opportunity to influence the FDA’s final rule—potentially resulting in compliance gaps or missed market opportunities.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product.

Key regulatory references include:

Course SKU
FR-26-3326-1

Replenish your Studio Course Advisor Unit balance here . Please contact frsales@courseavenue.com if you need to purchase more. Talk to use about an Enterprise License to see if that is right for you!

FDA’s Proposed Reclassification of Oncology Immunohistochemistry (IHC) Test Systems

$129.99

Why This Course is Important
Without this course, you could miss essential knowledge on upcoming regulatory changes, risk mitigation strategies, and the opportunity to influence the FDA’s final rule—potentially resulting in compliance gaps or missed market opportunities.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product.

Key regulatory references include:

Course SKU
FR-26-3326-1

Stay ahead in oncology diagnostics with a thorough course on the FDA’s proposed rule to reclassify immunohistochemistry (IHC) test systems used alongside approved oncology therapeutics. Gain detailed insights into the new regulatory landscape, covering the rationale for moving from class III (premarket approval) to class II (special controls), affected device codes, identified risks, and new expectations for performance data and labeling. This course prepares you for regulatory compliance, clinical implementation, and effective stakeholder participation in shaping future requirements.

In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification.
* Describe the regulatory framework for medical device classification.
* Identify the scope and types of IHC test systems affected.
* Recognize the risks and benefits associated with these devices.
* Explain the proposed special controls and their role in ensuring safety and effectiveness.
* Navigate the public comment process and understand the importance of stakeholder engagement.
* Appreciate that the rule is not final and may change based on public input.

Related products